☰

Acute Myeloid Leukemia Clinical Trials

Last reviewed: November 17, 2026

Start with whether AML is newly diagnosed, relapsed or refractory; list exact prior medicines, transplant history and molecular results. Older age alone does not determine fitness for intensive treatment. Trial age limits and physician-assessed fitness are separate requirements.

Answer a few questions to find clinical trials matched to your specific Acute Myeloid Leukemia situation.

Results usually take about 15 minutes after you submit. Email is optional. No sign-up.

Find matching trials →

Current Clinical Trial Landscape

Active research areas in 2026:

Already approved: Venetoclax + azacitidine, all-oral decitabine/cedazuridine (Inqovi) + venetoclax for newly diagnosed AML in patients ≥75 or unfit for intensive chemotherapy (FDA May 13, 2026; CR 41.6% in ASTX727-07), midostaurin/gilteritinib/quizartinib (FLT3), ivosidenib (IDH1), enasidenib (IDH2), menin inhibitors revumenib (R/R KMT2A-rearranged acute leukemia, Nov 2024; R/R NPM1-mutated AML, Oct 2025) and ziftomenib (Komzifti, R/R NPM1-mutated AML, Nov 2025), gemtuzumab ozogamicin (CD33), CPX-351.

Post-ASCO 2026 update (June 13): The menin inhibitor class is the AML headline of 2026. Revumenib (KMT2A-rearranged R/R approval Nov 2024) is being tested in Phase 3 frontline studies including NCT07211958 (with 7+3) and NCT06652438 (with HMA + venetoclax). Ziftomenib (NCT07007312) and bleximenib (NCT06852222, NCT07223814) are advancing in parallel. NPM1-mutated patients can discuss menin inhibitor studies with their treating team; mutation positivity alone does not establish eligibility. Separately, the FLT3 inhibitor class is expanding into FLT3-ITD negative disease with NCT06578247 (quizartinib + chemo; enrollment complete, awaiting readout).

Approved treatment versus research: US revumenib approval for susceptible NPM1-mutated relapsed/refractory AML applies from age 1 when no satisfactory alternative exists; ziftomenib applies to adults in that setting. Revumenib also has a separate KMT2A-translocation relapsed/refractory acute leukemia indication. These approvals do not establish eligibility for a frontline combination trial. Breakthrough designation is not approval.

Start with the exact wording of your molecular report, then check the study’s treatment setting and prior-treatment requirements. A mutation result alone does not establish eligibility. Use the sections below to find study examples to discuss with your hematology team.

What you knowWhere to start on this page
Your report lists an NPM1 mutation.Read NPM1-Mutated / KMT2A-Rearranged — Menin Inhibitors, then check which molecular result and treatment setting each study requires.
Your report lists a KMT2A rearrangement.Start with the same menin-inhibitor section, but check the exact cohort requirements. Do not assume that every result mentioning KMT2A matches a study requiring a rearrangement.
You have another molecular result, or are unsure what the report means.Look at Selected Trials by Molecular Subtype, including the FLT3, IDH1/IDH2 and TP53 sections. If you are unsure, keep the report’s wording and ask your team to clarify it rather than selecting a different result.
You are newly diagnosed or looking after relapse.Read Trials by Treatment Setting. Newly diagnosed and relapsed/refractory studies can have different entry requirements. Age limits and treatment fitness also need separate checks.
You are in remission or have a transplant history.Review Maintenance / Post-Remission and Transplant Optimization. Check when enrollment occurs and which previous treatments the study permits or requires.

Before checking a study, have these details ready:

Looking for a recruiting study? Open the linked registry record and check the recruitment label, relevant cohort and listed study sites. Then contact the study team about current local enrollment. A study marked recruiting overall may not have an open place at your preferred site.

You can begin a search with the information you know and leave uncertain molecular or treatment details as unknown. The study team must confirm eligibility and availability.

Selected Trials by Molecular Subtype

NPM1-Mutated / KMT2A-Rearranged — Menin Inhibitors

A major investigational drug class in AML. Menin inhibitors disrupt the menin–KMT2A interaction needed for HOX/MEIS1 gene activation in NPM1-mutated and KMT2A-rearranged leukemias. The Phase 3 combinations below mainly study newly diagnosed disease; they are not interchangeable with approved relapsed/refractory monotherapy indications:

FLT3-Mutated and FLT3-ITD Negative

FLT3-ITD and FLT3-TKD mutations occur in ~30% of AML. Trials combine FLT3 inhibitors with venetoclax, optimize post-transplant maintenance, and (new in 2026) extend the class into FLT3-ITD negative AML:

IDH1/IDH2-Mutated

TP53-Mutated

The highest unmet need in AML — TP53-mutated disease has extremely poor prognosis with current therapies. Multiple novel agents are in development including combinations with HMA + venetoclax backbones. Enter the exact TP53 variant, if known, together with treatment history. Some trials require a specific variant such as Y220C; generic TP53 positivity is insufficient, and matching does not confirm eligibility.

Trials by Treatment Setting

Newly Diagnosed — Intensive (Fit Patients)

Newly Diagnosed — Ineligible for Intensive Therapy

Relapsed / Refractory

Additional selected molecular and maintenance studies

Maintenance / Post-Remission

Transplant Optimization

Novel Approaches

A November 17 condition search for recruiting interventional AML studies returned 529 records, including 51 with a Phase 3 component; broad search results include transplant, supportive care and other acute leukemia settings, not 529 suitable treatment choices. Registry review November 17: NCT05183035 and NCT06578247 are active, not recruiting; NCT03793517 and NCT05726110 have unknown recruitment status. Confirm availability with the site. Age ranges are registry limits, not permission to enroll.

Primary regulatory sources: FDA revumenib; FDA ziftomenib; FDA oral decitabine/cedazuridine plus venetoclax. Each trial link opens its registry record.

Frequently Asked Questions

How do I find AML clinical trials for my mutation?

Use the guided questionnaire or paste a clinical summary with the exact molecular report, newly diagnosed versus relapsed/refractory status, prior treatments, transplant history and age. Include NPM1, FLT3-ITD/TKD, IDH1/2, KMT2A, TP53 and cytogenetics when available. The treating team and trial site must confirm eligibility.

What AML trials are currently recruiting?

Research includes menin, FLT3, IDH and BCL-2 approaches, induction combinations, post-remission treatment and transplant strategies. Current registry status, molecular cohort, prior treatment, age and fitness all matter. The selected list includes historical or unconfirmed studies with explicit status labels; it is not an eligibility determination.

Are there menin inhibitor trials open for NPM1-mutated AML?

Yes. Selected revumenib, ziftomenib and bleximenib combinations study untreated disease, with different intensive and non-intensive cohorts. Some require NPM1 mutation, some allow qualifying KMT2A rearrangements, and additional FLT3 or prior-treatment restrictions can apply. Approved relapsed/refractory monotherapy indications are separate.

Find AML Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific mutations, risk group, and treatment history.

Find Matching Trials